Rimonabant    (DrugBank: Rimonabant)

1 disease
IDDisease name (Link within this page)Number of trials
193Prader-Willi syndrome2

193. Prader-Willi syndrome    [ 95 clinical trials,   104 drugs,   (DrugBank: 27 drugs),   50 drug target genes,   63 drug target pathways]
Searched query = "Prader-Willi syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 95 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-006305-25-SE
(EUCTR)
15/02/200803/01/2008Effects of rimonabant (Acomplia) on obesity in adults with Prader-Willi SyndromeEffects of rimonabant (Acomplia) on obesity in adults with Prader-Willi Syndrome Obese adults with Prader Willi Syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10036476;Term: Prader-Willi syndrome
MedDRA version: 9.1;Classification code 10029883;Term: Obesity
Trade Name: ACOMPLIA 20 mg film-coated tabletsKarolinska University HospitalNULLNot RecruitingFemale: yes
Male: yes
Sweden
2NCT00603109
(ClinicalTrials.gov)
August 200715/1/2008Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi SyndromeEffect of Rimonabant, a Cannabinoid Receptor 1 Antagonist on Weight Gain and Body Composition in Adults With Prader Willi Syndrome.Prader-willi SyndromeDrug: rimonabant;Drug: placeboWeill Medical College of Cornell UniversityNational Institutes of Health (NIH);PWSAUSARecruiting18 Years35 YearsBoth18Phase 3United States